Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy

In patients with hypogammaglobulinemia secondary to chronic lymphocytic leukemia (CLL) or multiple myeloma (MM), intravenous immune globulin (IVIg) may be administered to reduce the risk of infection. Since 2013, IVIg products have carried a boxed safety warning about the risk of thromboembolic even...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Blood
Main Authors: Ammann, Eric M., Jones, Michael P., Link, Brian K., Carnahan, Ryan M., Winiecki, Scott K., Torner, James C., McDowell, Bradley D., Fireman, Bruce H., Chrischilles, Elizabeth A.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2016
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4713161/
https://ncbi.nlm.nih.gov/pubmed/26443622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-05-647552
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki